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Malignant pleural mesothelioma (MPM), which is linked to 
asbestos exposure and is a rare, lethal disease of the serosal 
membrane in the chest, has an incidence which continues 
to increase worldwide (1,2). MPM is histologically classified 
into three major subtypes: epithelioid, biphasic (or mixed) 
and sarcomatoid. Notwithstanding these well-defined MPM 
histological subtypes, there are tremendous differences 
in clinical outcomes including long-term survival in 
patients whose tumor histology is indistinguishable from 
conventional, highly aggressive MPM. 
MPM is generally diagnosed in the late stage where 
chemotherapy remains the only therapeutic option. 
Unfortunately, the efficacy of chemotherapy is modest, 
with a median overall survival of about 12 months (3). This 
limited efficacy has been associated with MPM’s ability 
to evade the immune system clearance and to establish an 
immune-suppressive environment (4,5). Consequently, it is 
not surprising that patients enrolled in the MAPS phase 3 
trial and in the LUME-Meso phase 2 trial benefited from 
the addition of bevacizumab and nintedanib to the standard 
cisplatin and pemetrexed backbone, respectively. In a small 
phase 1b non-randomized open-label study, the treatment 
with the anti-PD-1 monoclonal antibody pembrolizumab, 
was well tolerated, leading to a 20% response rate (RR) 
and a median duration of response of 12 months (95% 
CI: 6.8–40.7) in previously treated MPM patients (6). 
A phase 2 study of the same agent in previously treated 
MPM patients, unselected for PD-L1 expression, led to 
comparable results, showing an overall RR (ORR) of 22% 
and a disease-control rate (DCR) of 61% (7). Interestingly, 
the objective response was correlated to the PD-L1 
expression. Moreover, data with nivolumab in 27 MPM 
patients treated in the American Nivolumab Expanded Access 
Program showed an ORR of 24% while the DCR and the 
6-month survival rate were 60% and 52%, respectively (8). 
Similarly, phase 1 data on avelumab, which is another 
checkpoint inhibitor directed against PD-L1, demonstrated a 
lower RR (9.4%) but comparable median OS (10.9 months), 
which was even higher in PD-L1 positive cases (≥5% assessed 
by DAKO 73-10 antibody, 22.0 months) (9). 
To improve the efficacy of immune modulators and 
to counteract phenomena of resistance, the combination 
of immune checkpoint blocking antibodies has been 
investigated in other tumor types. In metastatic melanoma, 
for instance, the association of nivolumab with ipilimumab, 
whose combined use has been approved by the US Food and 
Drug Administration, has improved the overall survival (10). 
This  pivotal  c l inical  study has shed l ight on the 
fundamentals for using combinations of immune checkpoint 
blocking antibodies in different tumor types (11). In line 
with this, an NIBIT-MESO-1 trial (12), has recently 
investigated the activity of tremelimumab (anti-CTLA-4 
monoclonal antibody) in combination with durvalumab 
(anti-PD-L1 monoclonal antibody), in first- or second-
Editorial
NIBIT-MESO-1: limitations and clinical perspectives in MPM 
treatment testing an immune checkpoint blockade combination in 
a single-arm study 
Paolo Bironzo1, Riccardo Taulli2
1Thoracic Unit and Medical Oncology Division, Department of Oncology at San Luigi Hospital, University of Torino, Orbassano, Italy; 
2Department of Oncology, University of Torino, Torino, Italy
Correspondence to: Riccardo Taulli. Department of Oncology, University of Torino, Via Santena 5, 10126, Torino, Italy. Email: riccardo.taulli@unito.it.
Provenance: This is an invited Editorial commissioned by the Section Editor Zhenying Guo (Department of Pathology, Zhejiang Cancer Hospital, 
Hangzhou, China).
Comment on: Calabrò L, Morra A, Giannarelli D, et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): 
an open-label, non-randomised, phase 2 study. Lancet Respir Med 2018;6:451-60. 
Submitted Aug 03, 2018. Accepted for publication Sep 27, 2018.
doi: 10.21037/jtd.2018.09.135
View this article at: http://dx.doi.org/10.21037/jtd.2018.09.135
3881
S3879Journal of Thoracic Disease, Vol 10, Suppl 33 November 2018
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2018;10(Suppl 33):S3878-S3881jtd.amegroups.com
line treatment for MPM patients. The clinical activity of 
CTLA-4 blockade in monotherapy was previously reported 
in second-line treatment for MPM patients, although the 
efficacy was not confirmed in the randomized, placebo-
controlled phase 2 DETERMINE study (13,14). 
NIBIT-MESO-1 (12) is a single-arm, single-centre, 
open-label phase 2 study which included adult patients 
with histologically confirmed, unresectable pleural or 
peritoneal MM. Patient inclusions encompassed cases that 
had refused first-line chemotherapy, cases with disease 
progression during or after standard chemotherapy 
treatment, and patients with lesions measurable and suitable 
for repeated assessments according to standard evaluation 
criteria for both pleural and peritoneal MM. Patients 
excluded were those previously treated with monoclonal 
antibodies against CTLA-4, PD-1, or PD-L1 or those 
with active immune diseases or brain metastases. The 
pharmacokinetic was based on a previous, phase 1b trial in 
non-small-cell lung cancer. Specifically, the induction phase 
consisted of 4 cycles of tremelimumab (at the dosage of 
1 mg/kg) in association with durvalumab (at the dosage of 
20 mg/kg), both administered intravenously every 4 weeks. 
The maintenance phase consisted of durvalumab at the same 
dosage and schedules as in the induction, but administered 
for up to 9 cycles. Follow-up is still ongoing. The primary 
endpoint was the proportion of patients with an immune-
related objective response (complete response or partial 
response) according to immune-related criteria for patients 
with pleural and peritoneal mesothelioma. Secondary 
endpoints included safety, proportion of patients with 
immune-related disease control (complete response, partial 
response, or stable disease), immune-related progression-
free survival, progression-free survival, and overall survival. 
The association between individual efficacy endpoints 
and baseline PD-L1 levels was also included among the 
secondary endpoints. Safety was assessed monthly after each 
dose administration both during induction and maintenance 
phases. After the last administration of tremelimumab and 
durvalumab, safety was assessed every 30 days for up to 
90 days, while patients with severe adverse effects were 
monitored for one year.
Since fewer than 30% of all treatment-related adverse 
events (grade 3–4) were observed in the first 10 patients, all 
the originally planned patients (40 in total) were enrolled. 
Immune-related objective response was observed in 11 
patients and confirmed in 10 patients by CT scan. The 
median duration of immune-related partial response in 
these patients was 16.1 months and thus the study reached 
its primary endpoint. Immune-related disease control, 
with a median duration of 10.6 months, was observed in 26 
patients, while the median immune-related progression-free 
survival was 8 months, and immune-related progression-
free survival was 55% at 6 months and 28% at 12 months. 
Median progression-free survival and median overall 
survival were 5·7 and 16·6 months, respectively, with 25 
patients still being alive at 1 year. Sixty-eight percent of 
patients experienced grade 1 or 2 treatment-related adverse 
events (most dermatological), while grade 3 and 4 occurred 
in 18% of patients. No treatment-related deaths were 
reported. Overall, this study describes a tolerable safety 
profile for the combination and hints at its potentially 
clinical benefit. 
A recent French randomized phase 2 non-comparative 
study assessed the efficacy of nivolumab alone or in 
combination with ipilimumab in pre-treated advanced MPM 
patients. In the 62 patients treated in the combination arm, 
the median PFS was 5.6 and 4.0 months for those treated 
with nivolumab alone (n=63) (15). Although data are still 
not mature, at a median follow-up of 15 months, median 
OS was 13.6 months in the single-agent arm, while it was 
not even reached with the combination of drugs. 
Unfortunately, it is difficult make comparisons between 
the above studies due to the profound differences in the trial 
design, the enrolled populations (e.g., histological subtypes, 
percentage of peritoneal mesotheliomas, adopted response 
evaluation criteria) and the agents used (single-agent vs. 
combination therapies). However, in spite of such intrinsic 
limitations, the median progression-free survival and the 
median overall survival of the NIBIT-MESO-1 trial were 
comparable with those observed in the KEYNOTE-028 
study, in which patients were selected according to 
PD-L1 levels. Notably, in the NIBIT-MESO-1 trial, 
the level of PD-L1 at the baseline was not significantly 
associated to any clinical response (immune-related 
objective response, immune-related disease control, 
immune-related progression-free survival or 1-year overall 
survival). This observation is particularly relevant, since in 
many studies with immune modulators, the level of PD-L1 
is still considered a relevant parameter for effectiveness 
(16,17). However, the findings here reported suggest 
that additional criteria are urgently needed. A detailed 
molecular analysis at the genomic and transcriptional level 
of the tumor and the relative microenvironment, could 
be extremely informative in identifying novel critical 
biomarkers to improve patient stratification and selection. 
In other tumor types, the mutational burden (TMB) seems 
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to be a useful parameter in identifying good responders to 
immune modulators (18). 
Compared to other malignancies, MPM is characterized 
by fewer recurrent genetic alterations (19). At the same time, 
MPM is reported to be associated with very low TMB, as 
recently reported by Ladanyi and colleagues who analyzed The 
Cancer Genome Atlas (20). Yet, in the same study, the authors 
found that another negative immune checkpoint, VISTA, was 
highly expressed in this tumor as compared to the others, a fact 
which begs further research from future studies.
Unfortunately, these single-arm studies suggest hints of 
anti-cancer activity but do not allow us to draw any decisive 
conclusion in the absence of an internal comparative 
arm. Although there are no officially accepted second 
lines in MPM, non-approved agents such as gemcitabine 
vinorelbine are commonly used in this setting.
Overall, the NIBIT-MESO-1 study (12), despite its 
limitations, suggests that the combination of tremelimumab 
and durvalumab has an acceptable tolerability and leads 
to some clinical benefit in MM patients. The trade-offs 
between activity and toxicity do still need to be carefully 
assessed, and consequently, further well-designed studies 
are needed to extend and consolidate these findings. 
As pointed out by Calabrò et al., within this innovative 
context of combination therapies, the use of two-immune 
checkpoint blocking antibodies in association with other 
drugs might further improve clinical benefits in the near 
future. While ongoing clinical trials are mainly focusing on 
adding immune checkpoint inhibitors to chemotherapy in 
the first-line treatment, early preclinical data indicate that 
bromodomain inhibitors (BBIs) can be used as effective 
agents in restoring an immune-active environment in 
MPM (21). Nevertheless, caution should be applied before 
combining many drugs in a clinical trial, since the resulting 
toxicity may be intolerably exponential. 
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